Organization
Institute of Medical Oncology
1 abstract
Abstract
OMNIA-2: Phase I/II study of ANV419, an IL-2R-βγ targeted antibody-IL-2 fusion protein, in patients with relapsed or refractory multiple myeloma.Org: Anaveon, Institute of Medical Oncology, Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany, Lillebaelt Hospital, University Hospital of Southern Denmark,